Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry

https://doi.org/10.1016/S0002-9343(96)00060-5Get rights and content

Purpose

To assess the natural history and risk factors for thrombosis in a large cohort of unselected patients with antiphospholipid antibodies.

Patients and methods

Three hundred sixty consecutive patients (118 males, 242 females, median age 39 years [range 2 to 78]) fulfilling the currently accepted criteria for diagnosis of lupus anticoagulant (LAC) (n = 326) and/or raised immunoglobulin G anticardiolipin antibodies (IgG ACA) (n = 185) were collected from 16 Italian institutions and prospectively observed for a median of 3.9 years (range 0.5 to 5). Main endpoints were the occurrence of arterial or venous thrombosis, the outcome of pregnancies, and any severe complications leading to hospitalization or death.

Results

Thirty-four patients developed a thrombotic complication, with a total incidence of 2.5% patient-years. Multivariate logistic regression analysis identified two independent risk factors for thrombotic events: a previous thrombosis (RR 4.9; 95% Cl, 1.76 to 13.7; P < 0.005) and IgG ACA titer above 40 units (RR 3.66; 95% Cl, 1.24 to 10.8; P < 0.01). A total of 28 pregnancies were observed in 25 women and 11 (39%) were abortive. Adverse pregnancy outcomes were significantly more frequent in women with a history of miscarriage or vascular occlusion (9/16, 56%) than in asymptomatic women (2/12, 17%) (P = 0.035). Four patients developed non-Hodgkin's lymphoma during the follow-up. Eighteen patients died. Vascular events and hematological malignancies represented the most frequent causes of death (n = 5 for each).

Conclusions

The present study shows that: (a) previous thrombosis and ACA titer > 40 U are independent predictors of thrombosis; (b) history of miscarriage or vascular disease is significantly associated with adverse pregnancy outcome; (c) hematological malignancies can develop during follow-up in patients with antiphospholipid antibodies.

References (38)

  • GalliM et al.

    Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependendent and b2-glycoprotein l-dependent antiphospholipid antibodies

    Blood

    (1995)
  • McNeilHP et al.

    Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: b2-glycoprotein I (Apolipoprotein H)

  • BeversEM et al.

    Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin

    Thromb Haemostas

    (1991)
  • LoizouS et al.

    Measurement of anticardiolipin antibodies by an enzymelinked immunosorbent assay: standardization and quantitation of results

    Clin Exp Immunol

    (1986)
  • TriplettDA

    Assays for detection of antiphospholipid antibodies

    Lupus

    (1994)
  • LovePE et al.

    Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in the systemic lupus erythematosus (SLE) and in non-SLE disorders

    Ann Intern Med

    (1990)
  • VilaP et al.

    Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects

    Thromb Haemostas

    (1994)
  • LongAA et al.

    The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study

    Thromb Haemostas

    (1991)
  • BarbuiT

    Finazzi G

    Clinical trials on antiphospholipid syndrome: what is being done and what is needed? Lupus

    (1994)
  • Cited by (401)

    • Pulmonary embolism and pregnancy

      2021, Praticien en Anesthesie Reanimation
    • Hematologic Disorders and Stroke

      2021, Stroke: Pathophysiology, Diagnosis, and Management
    • Antiphospholipid antibodies and lower extremity peripheral artery disease: A systematic review and meta-analysis

      2020, Seminars in Arthritis and Rheumatism
      Citation Excerpt :

      However, these statistical findings are limited in interpretation. APL were measured only once in most studies and, where reported, the average IgG aCL titres did not reach the thrombogenic threshold of 40 GPL derived from a multicentre survey on APS patients during the mid 1990′s [40] (though some studies reported few individual values higher than 40 GPL) and. despite the linear relation between IgG aCL and intima media thickness of carotid arteries in APS [41] no atherogenic threshold has ever been detected or calculated.

    • Antiphospholipid syndrome

      2020, Translational Research
    View all citing articles on Scopus
    View full text